Cargando…
免疫检查点抑制剂相关性重症肌无力：从诊断到治疗
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Myasthenia gravis (MG)...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467994/ https://www.ncbi.nlm.nih.gov/pubmed/32752585 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.25 |
| _version_ | 1783578131086442496 |
|---|---|
| collection | PubMed |
| description | Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Myasthenia gravis (MG) is one of rare but life-threatening irAEs, with acute onset and rapid progression after ICI initiation. Early diagnosis and active treatment are crucial. Herein, we review recent literatures to provide guidance to frequently asked questions concerning the diagnosis and management of ICI-MG. |
| format | Online Article Text |
| id | pubmed-7467994 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74679942020-09-03 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 Zhongguo Fei Ai Za Zhi 综述 Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in the treatment of various tumor types. Despite the favorable results in terms of oncological outcomes, these treatments have been associated with a variety of immune-related adverse events (irAEs). Myasthenia gravis (MG) is one of rare but life-threatening irAEs, with acute onset and rapid progression after ICI initiation. Early diagnosis and active treatment are crucial. Herein, we review recent literatures to provide guidance to frequently asked questions concerning the diagnosis and management of ICI-MG. 中国肺癌杂志编辑部 2020-08-20 /pmc/articles/PMC7467994/ /pubmed/32752585 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.25 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 综述 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title_full | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title_fullStr | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title_full_unstemmed | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title_short | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| title_sort | 免疫检查点抑制剂相关性重症肌无力：从诊断到治疗 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467994/ https://www.ncbi.nlm.nih.gov/pubmed/32752585 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.25 |
| work_keys_str_mv | AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānxìngzhòngzhèngjīwúlìcóngzhěnduàndàozhìliáo AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānxìngzhòngzhèngjīwúlìcóngzhěnduàndàozhìliáo AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānxìngzhòngzhèngjīwúlìcóngzhěnduàndàozhìliáo AT miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānxìngzhòngzhèngjīwúlìcóngzhěnduàndàozhìliáo |